Genetics of allogeneic hematopoietic cell transplantation. Role of HLA matching, functional variation in immune response genes

Immunologic Research

Volumn 41, Issue 1, 2008, Pages 56-78

  Hansen, John A ^a,b   Petersdorf, Effie W ^a,b   Lin, Ming Tseh ^c   Wang, Steven ^a   Chien, Jason W ^a,b   Storer, Barry ^a   Martin, Paul J ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Genetic variation; HLA matching; Human major histocompatibility complex; Immune response genes; Single nucleotide polymorphisms (SNPs)

Indexed keywords

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOIMMUNITY; GENETIC VARIABILITY; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HLA MATCHING; HUMAN; IMMUNE RESPONSE; IMMUNOGENETICS; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE;

ANIMALS; CYTOKINES; GENOTYPE; GRAFT REJECTION; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS); PROPORTIONAL HAZARDS MODELS; RECURRENCE; RISK FACTORS; SURVIVAL ANALYSIS; TRANSPLANTATION, HOMOLOGOUS;

EID: 46149105947     PISSN: 0257277X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12026-007-0043-x     Document Type: Review

References (122)

1. Elkins WL. Cellular immunology, the pathogenesis of graft versus host reactions (review). Prog Allergy 1971;15:78-187.
2. Martin PJ, Hansen J, Storb R, Thomas ED. Human marrow transplantation: an immunological perspective. In: Dixon FJ, Austen KF, Hood LE, Uhr JW, editors. Advances in immunology. Orlando: Florida, Academic Press; 1987. p. 379-438.
3. Martin PJ. Overview of hematopoietic cell transplantation immunology. In: Blume KG, Forman SJ, Appelbaum FR, editors. Thomas' hematopoietic cell transplantation. 3rd ed. Oxford, UK: Blackwell Publishing Ltd; 2004. p. 16-30.
4. Snell GD, Dausset J, Nathenson S. Histocompatibility. New York, NY: Academic Press; 1976.
5. Perreault C, Décary F, Brochu S, Gyger M, Bélanger R, Roy D. Minor Histocompatibility Antigens. Blood 1990;76:1269-1280.
6. Martin PJ. Increased disparity for minor histocompatibility antigens as a potential cause of increased GVHD risk in marrow transplantation from unrelated donors compared with related donors. Bone Marrow Transplant 1991;8:217-23.
7. Karabon L, Wysoczanska B, Bogunia-Kubik K, Suchnicki K, Lange A. IL-6 and IL-10 promoter gene polymorphisms of patients and donors of allogeneic sibling hematopoietic stem cell transplants associate with the risk of acute graft-versus-host disease. Hum Immunol 2005;66:700-10.
8. Holler E, Rogler G, Brenmoehl J, Hahn J, Herfarth H, Greinix H, Dickinson AM, Socie G, Wolff D, Fischer G, Jackson G, Rocha V, Steiner B, Eissner G, Marienhagen J, Schoelmerich J, Andreesen R. Prognostic significance of NOD2/CARD15 variants in HLA-identical sibling hematopoietic stem cell transplantation: effect on long term outcome is confirmed in 2 independent cohorts and may be modulated by the type of gastrointestinal decontamination. Blood 2006;prepublished online January 19, 2006; DOI 10.1182/blood-2005-09-3741.
9. Middleton PG, Taylor PRA, Jackson G, Proctor SJ, Dickinson AM. Cytokine gene polymorphisms associating with severe acute graft-versus-host disease in HLA-identical sibling transplants. Blood 1998;92:3943-8.
10. Socie G, Loiseau P, Tamouza R, Janin A, Busson M, Gluckman E, Charron D. Both genetic and clinical factors predict the development of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Transplantation 2001;72:699-706.
11. Cavet J, Dickinson AM, Norden J, Taylor PR, Jackson GH, Middleton PG. Interferon-gamma and interleukin-6 gene polymorphisms associate with graft-versus-host disease in HLA-matched sibling bone marrow transplantation. Blood 2001;98:1594-600.
12. Cullup H, Dickinson AM, Jackson GH, Taylor PR, Cavet J, Middleton PG. Donor interleukin 1 receptor antagonist genotype associated with acute graft-versus-host disease in human leucocyte antigen-matched sibling allogeneic transplants. Br J Haematol 2001;113:807-13.
13. Rocha V, Franco RF, Porcher R, Bittencourt H, Silva WAJ, Latouche A, Devergie A, Esperou H, Ribaud P, Socie G, Zago MA, Gluckman E. Host defense and inflammatory gene polymorphisms are associated with outcomes after HLA-identical sibling bone marrow transplantation. Blood 2002;100:3908-18.
14. Lin M-T, Storer B, Martin PJ, Tseng L-H, Gooley T, Chen P-J, Hansen JA. Relation of an interleukin-10 promoter polymorphism to graft-versus-host disease and survival after hematopoietic-cell transplantation. N Engl J Med 2003;349:2201-10.
15. Mullighan C, Heatley S, Doherty K, Szabo F, Grigg A, Hughes T, Schwarer A, Szer J, Tait B, To B, Bardy P. Non-HLA immunogenetic polymorphisms and the risk of complications after allogeneic hemopoietic stem-cell transplantation. Transplantation 2004;27:587-96.
16. Lin M-T, Storer B, Martin PJ, Tseng L-H, Grogan B, Chen P-J, Zhao LP, Hansen JA. Genetic variation in the IL-10 pathway modulates severity of acute graft-versus-host disease following hematopoietic cell transplantation: synergism between IL-10 genotype of patient and IL-10 receptor β genotype of donor. Blood 2005;106:3995-4001.
17. Keen LJ, Defor TE, Bidwell JL, Davies SM, Bradley BA, Hows JM. Interleukin-10 and tumor necrosis factor alpha region haplotypes predict transplant-related mortality after unrelated donor stem cell transplantation. Blood 2004;103:3599-602.
18. Cavet J, Middleton PG, Segall M, Noreen H, Davies SM, Dickinson AM. Recipient tumor necrosis factor-alpha and interleukin-10 gene polymorphisms associate with early mortality and acute graft-versus-host disease severity in HLA-matched sibling bone marrow transplants. Blood 1999;94:3941-46.
19. Seo KW, Kim DH, Sohn SK, Lee NY, Chang HH, Kim SW, Jeon SB, Baek JH, Kim JG, Suh JS, Lee KB. Protective role of interleukin-10 promoter gene polymorphism in the pathogenesis of invasive pulmonary aspergillosis after allogeneic stem cell transplantation. Bone Marrow Transplant 2005;36:1089-95.
20. Bogunia-Kubik K, Mlynarczewska A, Jaskula E, Lange A. The presence of IFNG 3/3 genotype in the recipient associates with increased risk for epstein-barr virus reactivation after allogeneic haematopoietic stem cell transplantation. Br J Haematol 2006;132:326-32.
21. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, Lerner KG, Thomas ED. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974;18:295-304.
22. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, Martin P, Chien J, Prezepiorka D, Couriel D, Cowen EW, Dinndorf P, Farrell A, Hartzman R, Henslee-Downey J, Jacobsohn D, McDonald G, Mittleman B, Rizzo JD, Robinson M, Schubert M, Schultz K, Shulman H, Turner M, Vogelsang G, Flowers MED. National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005;11:945-56.
23. Nash RA, Pepe MS, Storb R, Longton G, Pettinger M, Anasetti C, Appelbaum FR, Bowden R, Deeg HJ, Doney K, Martin PJ, Sullivan KM, Sanders J, Witherspoon RP. Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate. Blood 1992;80:1838-45.
24. Przepiorka D, Weisdorf D, Martin P, Klingemann H-G, Beatty P, Hows J, Thomas ED. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant 1995;15:825-8.
25. Stewart BL, Storer B, Storek J, Deeg HJ, Storb R, Hansen JA, Appelbaum FR, Carpenter PA, Sanders JE, Kiem H-P, Nash RA, Petersdorf EW, Moravec C, Morton AJ, Anasetti C, Flowers MED, Martin PJ. Duration of immunosuppressive treatment for chronic graft-versus-host disease. Blood 2004;104:3501-6.
26. Martin PJ, McDonald GB, Sanders JE, Anasetti C, Appelbaum FR, Deeg HJ, Nash RA, Petersdorf EW, Hansen JA, Storb R. Increasingly frequent diagnosis of acute gastrointestinal graft-versus-host disease after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2004;10:320-7.
27. Przepiorka D, Smith TL, Folloder J, Khouri I, Ueno NT, Mehra R, Körbling M, Huh YO, Giralt S, Gajewski J, Donato M, Cleary K, Claxton D, Braunschweig I, van Besien K, Andersson BS, Anderlini P, Champlin R. Risk factors for acute graft-versus-host disese after allogeneic blood stem cell transplantation. Blood 1999;94:1465-70.
28. Mielcarek M, Martin PJ, Leisenring W, Flowers MED, Maloney DG, Sandmaier BM, Maris MB, Storb R. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 2003;102:756-62.
29. Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE, Hackman R, Tsoi MS, Storb R, Thomas ED. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980;69:204-17.
30. Martin P, Slavin S. Workshop summary: graft versus host disease. In: Gale RP, Champlin R, editors. Progress in bone marrow transplantation. New York: Alan R. Liss, Inc; 1987. p. 277-280.
31. Atkinson K, Horowitz MM, Gale RP, van Bekkum DW, Gluckman E, Good RA, Jacobsen N, Kolb H-J, Rimm AA, Ringdén O, Rozman C, Sobocinski KA, Zwaan FE, Bortin MM. Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation. Blood 1990;75:2459-64.
32. Sullivan KM. Graft-versus-host disease. In: Thomas ED, Blume KG, Forman SJ, editors. Hematopoietic cell transplantation. 2nd ed. Malden, MA: Blackwell Sciences, Inc.; 1999. p. 515-36.
33. Sale GE, Shulman HM, Hackman RC. Pathology of hematopoietic cell transplantation. In: Blume KG, Forman SJ, Appelbaum FR, editors. Thomas' hematopoietic cell transplantation. 3rd ed. Oxford, UK: Blackwell Publishing Ltd.; 2004. p. 286-99.
34. Beilhack A, Schulz S, Baker J, Beilhack GF, Wieland CB, Herman EI, Baker EM, Cao YA, Contag CH, Negrin RS. In vivo analyses of early events in acute graft-versus-host disease reveal sequential infiltration of T-cell subsets. Blood 2005;106:1113-22.
35. Ferrara JLM, Deeg HJ. Graft-versus-host disease (review). N Engl J Med 1991;324:667-74.
36. Antin JH, Ferrara JLM. Cytokine dysregulation and acute graft-versus-host disease. Blood 1992;80:2964-8.
37. Jadus MR, Websic HT. The role of cytokines in graft-versus-host reactions and disease. Bone Marrow Transplant 1992;10:1-14.
38. Nestel FP, Price KS, Seemayer TA, Lapp WS. Macrophage priming and lipopolysaccharide-triggered release of tumor necrosis factor α during graft-versus-host disease. J Exp Med 1992;175:405-13.
39. Holler E, Kolb HJ, Mittermuller J, Kaul M, Ledderose G, Duell T, Seeber B, Schleuning M, Hintermeier-Knabe R, Ertl B. Modulation of acute graft-versus-host-disease after allogeneic bone marrow transplantation by tumor necrosis factor alpha (TNF alpha) release in the course of pretransplant conditioning: role of conditioning regimens and prophylactic application of a monoclonal antibody neutralizing human TNF alpha (MAK 195F). Blood 1995;86:890-9.
40. Krenger W, Hill GR, Ferrara JL. Cytokine cascades in acute graft-versus-host disease (review). Transplantation 1997;64:553-8.
41. Przepiorka D, Anderlini P, Saliba R, Cleary K, Mehra R, Khouri I, Huh YO, Giralt S, Braunschweig I, van Besien K, Champlin R. Chronic graft-versus-host disease after allogeneic blood stem cell transplantation. Blood 2001;98:1695-700.
42. Remberger M, Kumlien G, Aschan J, Barkholt L, Hentschke P, Ljungman P, Mattsson J, Svennilson J, Ringdén O. Risk factors for moderate-to-severe chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2002;8:674-82.
43. Shulman HM, Kleiner D, Lee SJ, Morton T, Pavletic SZ, Farmer E, Moresi JM, Greenson J, Janin A, Martin PJ, McDonald G, Flowers MED, Turner M, Atkinson J, Lefkowitch J, Washington MK, Prieto VG, Kim SK, Argenyi Z, Diwan AH, Rashid A, Hiatt K, Couriel D, Schultz K, Hymes S, Vogelsang GB. Histopathologic diagnosis of chronic graft-versus-host disease: National Institutes of Health Consensus Development project on criteria for clinical trials in chronic graft-versus-host disease: II. Pathology working group report. Biol Blood Marrow Transplant 2006;12:31-47.
44. Dausset J. Leuco-agglutinins IV. Leuco-agglutinins and bloodtransfusion. Vox Sang 1954;4:190-8.
45. Terasaki PI, McClelland JD. Microdroplet assay of human serum cytotoxins. Nature 1964;204:998-1000.
46. van Rood JJ, van Leeuwen A. Leukocyte grouping. A method and its application. J Clin Investig 1963;42:1382-90.
47. Payne R, Tripp M, Weigle J, Bodmer W, Bodmer J. A new leukocyte isoantigen system in man. Cold Spring Harbor Symp Quant Biol 1964;29:285-94.
48. Amos DB. Determination of histocompatibility: the inheritance of leukocyte antigens. Transplantation 1967;5:1015-23.
49. Bach FH, Amos DB. HU-1: major histocompatibility locus in man. Science 1967;156:1506-8.
50. Bach F, Hirschhorn K. Lymphocyte interaction: a potential histocompatibility test in vitro. Science 1964;143:813-4.
51. Cerottini JC, Brunner KT. Cell-mediated cytotoxicity, allograft rejection, and tumor immunity (review). Adv Immunol 1974;18:67-132.
52. Dupont B, Hansen JA, Yunis EJ. Human mixed lymphocyte culture reactions: genetics, specificity and biological implications. Adv Immunol 1976;23:107-202.
53. Gatti RA, Meuwissen HJ, Allen HD, Hong R, Good RA. Immunological reconstitution of sex-linked lymphopenic immunological deficiency. Lancet 1968;2:1366-9.
54. Thomas ED, Buckner CD, Rudolph RH, Fefer A, Storb R, Neiman PE, Bryant JI, Chard RL, Clift RA, Epstein RB, Fialkow PJ, Funk DD, Giblett ER, Lerner KG, Reynolds FA, Slichter S. Allogeneic marrow grafting for hematologic malignancy using HL-A matched donor-recipient sibling pairs. Blood 1971;38:267-87.
55. Good RA. Cellular immunology in a historical perspective. Immunol Rev 2002;185:136-58.
56. Thomas ED. Bone marrow transplantation - past, present and future: nobel lecture, December 8, 1990. In: Frängsmyr T, editor. Les Prix nobel: the nobel prizes 1990. Stockholm, Sweden: Nobel Foundation; 1990.p. 222-30.
57. Buckley RH. Reconstitution: grafting of bone marrow and thymus. In: Amos B, editor. Progress in immunology. New York, NY: Academic Press; 1971.p. 1061-80.
58. van Bekkum DW. Use and abuse of hemopoietic cell grafts in immune deficiency diseases. Transplant Rev 1972;9:3-53.
59. Dupont B, O'Reilly RJ, Jersild C, Good RA. Transplantation of immunocompetent cells. In: Brent L, Holborow EJ, editors. Progress in immunology II: Proceedings of the second international congress of immunology, Brighton, United Kingdom, July 21-21, 1974. New York, NY: Elsevier Publishing Company; 1974. p. 203-14.
60. Thomas ED, Buckner CD, Storb R, Neiman PE, Fefer A, Clift RA, Slichter SJ, Funk DD, Bryant JI, Lerner KG. Aplastic anaemia treated by marrow transplantation. Lancet 1972;1:284-9.
61. Thomas ED, Storb R, Clift RA, Fefer A, Johnson FL, Neiman PE, Lerner KG, Glucksberg H, Buckner CD. Bone-marrow transplantation. N Engl J Med 1975;292:832-843, 895-902.
62. Copenhagen Study Group of Immunodeficiencies. Bone-marrow transplantation from an HL-A non-identical but mixed-lymphocyte-culture identical donor. Lancet 1973;1:1146-50.
63. Vossen JM, de Koning J, van Bekkum DW, Dicke KA, Eysvoogel VP, Hijmans W, van Loghem E, Radl J, van Rood JJ, van der Waay D, Dooren LJ. Successful treatment of an infant with severe combined immunodeficiency by transplantation of bone marrow cells from an uncle. Clin Exp Immunol 1973;13:9-20.
64. Geha RS, Malakian A, LeFranc G, Chayban D, Serre JL. Immunologic reconstitution in severe combined immunodeficiency following transplantation with parental bone marrow. Pediatrics 1976;58:451-5.
65. Niethammer D, Goldmann SF, Haas RJ, Dietrich M, Flad H-D, Fliedner TM, Kleihauer E. Bone marrow transplanation for severe combined immunodeficiency with the HL-A-incompatible but MLC-identical mother as a donor. Transplant Proc 1976;8:623-8.
66. Speck B, Zwaan FE, van Rood JJ, Eernisse JG. Allogeneic bone marrow transplantation in a patient with aplastic anemia using a phenotypically HLA-A-identical unrelated donor. Transplantation 1973;16:24-8.
67. L'Esperance P, Hansen JA, Jersild C, O'Reilly R, Good RA, Thomsen M, Nielsen LS, Svejgaard A, Dupont B. Bone-marrow donor selection among unrelated four-locus identical individuals. Transplant Proc 1975;Suppl.1:823-31.
68. Horowitz SD, Bach FH, Groshong T, Hong R, Yunis EJ. Treatment of severe combined immunodeficiency with bone-marrow from an unrelated, mixed-leukocyte-culture-non-reactive donor. Lancet 1975;2:431-3.
69. Opelz G, Gale RP, Feig SA, Walker J, Terasaki PI, Saxon A. Significance of HLA and non-HLA antigens in bone marrow transplantation. Transplant Proc 1978;10:43-6.
70. Clift RA, Hansen JA, Thomas ED, Buckner CD, Sanders JE, Mickelson EM, Storb R, Johnson FL, Singer JW, Goodell BW. Marrow transplantation from donors other than HLA-identical siblings. Transplantation 1979;28:235-42.
71. Hansen JA, Clift RA, Mickelson EM, Nisperos B, Thomas ED. Marrow transplantation from donors other than HLA identical siblings. Hum Immunol 1981;1:31-40.
72. Beatty PG, Clift RA, Mickelson EM, Nisperos B, Flournoy N, Martin PJ, Sanders JE, Stewart P, Buckner CD, Storb R, Thomas ED, Hansen JA. Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med 1985;313:765-71.
73. Anasetti C, Hansen JA. Effect of HLA incompatibility in marrow transplantation from unrelated and HLA-mismatched related donors. Transfus Sci 1994;15:221-30.
74. Anasetti C, Amos D, Beatty PG, Appelbaum FR, Bensinger W, Buckner CD, Clift R, Doney K, Martin PJ, Mickelson E, Nisperos B, O'Quigley J, Ramberg R, Sanders JE, Stewart P, Storb R, Sullivan KM, Witherspoon RP, Thomas ED, Hansen JA. Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. N Engl J Med 1989;320:197-204.
75. Anasetti C, Beatty PG, Storb R, Martin PJ, Mori M, Sanders JE, Thomas ED, Hansen JA. Effect of HLA incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphoma. Hum Immunol 1990;29:79-91.
76. Lohrmann H-P, Dietrich M, Goldmann SF, Kristensen T, Fliedner TM, Abt C, Pflieger H, Flad H-D, Kubanek B, Heimpel H. Bone marrow transplantation for aplastic anaemia from a HL-A and MLC-identical unrelated donor. Blut 1975;31:347-54.
77. O'Reilly RJ, Dupont B, Pahwa S, Grimes E, Smithwick EM, Pahwa R, Schwartz S, Hansen JA, Siegal FP, Sorell M, Svejgaard A, Jersild C, Thomsen M, Platz P, L'Esperance P, Good RA. Reconstitution in severe combined immunodeficiency by transplantation of marrow from an unrelated donor. N Engl J Med 1977;297:1311-8.
78. Hansen JA, Clift RA, Thomas ED, Buckner CD, Storb R, Giblett ER. Transplantation of marrow from an unrelated donor to a patient with acute leukemia. N Engl J Med 1980;303:565-7.
79. Beatty PG, Dahlberg S, Mickelson EM, Nisperos B, Opelz G, Martin PJ, Hansen JA. Probability of finding HLA-matched unrelated marrow donors. Transplantation 1988;45:714-8.
80. McCullough J, Hansen J, Perkins H, Stroncek D, Bartsch G. The National Marrow Donor Program: how it works, accomplishments to date. Oncology 1989;3:63-72.
81. Oudshoorn M, van Leeuwen A, van der Zanden HG, van Rood JJ. Bone marrow donors worldwide: a successful exercise in international cooperation. Bone Marrow Transplant 1994;14:3-8.
82. Hansen JA. Development of registries of HLA-typed volunteer marrow donors (editorial). Tissue Antigens 1996;47:460-3.
83. Beatty PG, Hansen JA, Longton GM, Thomas ED, Sanders JE, Martin PJ, Bearman SI, Anasetti C, Petersdorf EW, Mickelson EM, Pepe MS, Appelbaum FR, Buckner CD, Clift RA, Petersen FB, Stewart PS, Storb RF, Sullivan KM, Tesler MC, Witherspoon RP. Marrow transplantation from HLA-matched unrelated donors for treatment of hematologic malignancies. Transplantation 1991;51:443-7.
84. McGlave PB, Beatty P, Ash R, Hows JM. Therapy for chronic myelogenous leukemia with unrelated donor bone marrow transplantation: results in 102 cases. Blood 1990;75:1728-32.
85. Beatty PG, Anasetti C, Hansen JA, Longton GM, Sanders JE, Martin PJ, Mickelson EM, Choo SY, Petersdorf EW, Pepe MS, Appelbaum FR, Bearman SI, Buckner CD, Clift RA, Petersen FB, Singer J, Stewart PS, Storb RF, Sullivan KM, Tesler MC, Witherspoon RP, Thomas ED. Marrow transplantation from unrelated donors for treatment of hematologic malignancies: effect of mismatching for one HLA locus. Blood 1993;81:249-53.
86. Kernan NA, Bartsch G, Ash RC, Beatty PG, Champlin R, Filipovich A, Gajewski J, Hansen JA, Henslee-Downey J, McCullough J, McGlave P, Perkins HA, Phillips GL, Sanders J, Stroncek D, Thomas ED, Blume KG. Analysis of 462 transplantations from unrelated donors facilitated by The National Marrow Donor Program. N Engl J Med 1993;328:593-602.
87. Petersdorf EW, Longton GM, Anasetti C, Mickelson EM, McKinney SK, Smith AG, Martin PJ, Hansen JA. Association of HLA-C disparity with graft failure after marrow transplantation from unrelated donors. Blood 1997;89:1818-23.
88. Petersdorf EW, Hansen JA, Martin PJ, Woolfrey A, Malkki M, Gooley T, Storer B, Mickelson E, Smith A, Anasetti C. Major-histocompatibility-complex class I alleles and antigens in hematopoietic-cell transplantation. N Engl J Med 2001;345:1794-800.
89. Petersdorf EW, Gooley TA, Anasetti C, Martin PJ, Smith AG, Mickelson EM, Woolfrey AE, Hansen JA. Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient. Blood 1998;92:3515-20.
90. Sasazuki T, Juji T, Morishima Y, Kinukawa N, Kashiwabara H, Inoko H, Yoshida T, Kimura A, Akaza T, Kamikawaji N, Kodera Y, Takaku F. Effect of matching of class I HLA alleles on clinical outcome after transplantation of hematopoietic stem cells from an unrelated donor. N Engl J Med 1998;339:1177-85.
91. Morishima Y, Sasazuki T, Inoko H, Juji T, Akaza T, Yamamoto K, Ishikawa Y, Kato S, Sao H, Sakamaki H, Kawa K, Hamajima N, Asano S, Kodera Y. The Clinical significance of human leukocyte antigen (HLA) allele compatibility in patients receiving a marrow transplant from serologically HLA-A, HLA-B, and HLA-DR matched unrelated donors. Blood 2002;99:4200-6.
92. Flomenberg N, Baxter-Lowe LA, Confer D, Fernandez-Vina M, Filipovich A, Horowitz M, Hurley C, Kollman C, Anasetti C, Noreen H, Begovich A, Hildebrand W, Petersdorf E, Schmeckpeper B, Setterholm M, Trachtenberg E, Williams T, Yunis E, Weisdorf D. Impact of HLA class I and class II high resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplant outcome. Blood 2004;104:1923-30.
93. Lee SJ, Klein J, Haagenson M, Baxter-Lowe LA, Confer DL, Eapen M, Fernandez-Vina M, Flomenberg N, Horowitz M, Hurley CK, Noreen H, Oudshoorn M, Petersdorf E, Setterholm M, Spellman S, Weisdorf D, Williams TM, Anasetti C. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood First Edition Paper, prepublished online September 4, 2007.
94. Kawase T, Morishima Y, Matsuo K, Kashiwase K, Inoko H, Saji H, Kato S, Juji T, Kodera Y, Sasazuki T. The Japan Marrow Donor Program. High-risk HLA allele mismatch combinations responsible for severe acute graft-versus-host disease and implication for its molecular mechanism. Blood 2007;110:2235-2241.
95. Cullup H, Dickinson AM, Cavet J, Jackson GH, Middleton PG. Polymorphisms of interleukin-1 alpha constitute independent risk factors for chronic graft-versus-host disease after allogeneic bone marrow transplantation. Br J Haematol 2003;122:778-87.
96. MacMillan ML, Radloff GA, Defor TE, Weisdorf DJ, Davies SM. Interleukin-1 genotype and outcome of unrelated donor bone marrow transplantation. Br J Haematol 2003;121:597-604.
97. Kim DH, Lee NY, Sohn SK, Baek JH, Kim JG, Suh JS, Lee KB, Shin IH. IL-10 promoter gene polymorphism associated with the occurrence of chronic GVHD and its clinical course during systemic immunosuppressive treatment for chronic GVHD after allogeneic peripheral blood stem cell transplantation. Transplantation 2005;79:1615-22.
98. Holler E, Rogler G, Herfarth H, Brenmoehl J, Wild PJ, Hahn J, Eissner G, Scholmerich J, Andreesen R. Both donor and recipient NOD2/CARD15 mutations associate with transplant-related mortality and GvHD following allogeneic stem cell transplantation. Blood 2004;104:889-94.
99. Murphy WJ, Welniak LA, Taub DD, Wiltrout RH, Taylor PA, Vallera DA, Kopf M, Young H, Longo DL, Blazar BR. Differential effects of the absence of interferon-gamma and IL-4 in acute graft-versus-host disease after allogeneic bone marrow transplantation in mice. J Clin Invest 1998;102:1742-1748.
100. Yang YG, Dey BR, Sergio JJ, Pearson DA, Sykes M. Donor-derived interferon gamma is required for inhibition of acute graft-versus-host disease by interleukin 12. J Clin Invest 1998;102:2126-35.
101. Hulkkonen J, Pertovaara M, Antonen J, Pasternack A, Hurme M. Elevated interleukin-6 plasma levels are regulated by the promoter region polymorphism of the IL6 gene in primary Sjogren's syndrome and correlate with the clinical manifestations of the disease. Rheumatology (Oxford ) 2001;40:656-61.
102. Epler GR, Colby TV. The spectrum of Bronchiolitis Obliterans. Chest 1983;83:161-2.
103. Ralph DD, Springmeyer SC, Sullivan KM, Hackman RC, Storb R, Thomas ED. Rapidly progressive air-flow obstruction in marrow transplant recipients: possible association between obliterative bronchiolitis and chronic graft-versus-host disease. Am Rev Respir Dis 1984;129:641-4.
104. Ostrow D, Buskard N, Hill RS, Vickars L, Churg A. Bronchiolitis obliterans complicating bone marrow transplantation. Chest 1985;87:828-30.
105. Johnson FL, Stokes DC, Ruggiero M, Dalla-Pozza L, Callihan TR. Chronic obstructive airways disease after bone marrow transplantation (review). J Pediatr 1984;105:370-6.
106. Chien JW, Martin PJ, Gooley TA, Flowers ME, Heckbert SR, Nichols WG, Clark JG. Airflow obstruction after myeloablative allogeneic hematopoietic stem cell transplantation. Am J Respir Crit Care Med 2003;168:208-14.
107. Clark JG, Schwartz DA, Flournoy N, Sullivan KM, Crawford SW, Thomas ED. Risk factors for airflow obstruction in recipients of bone marrow transplants. Ann Intern Med 1987;107:648-56.
108. Tait RC, Burnett AK, Robertson AG, McNee S, Riyami BMS, Carter R, Stevenson RD. Subclinical pulmonary function defects following autologous and allogeneic bone marrow transplantation: relationship to total body irradiation and graft-versus-host disease. Int J Radiat Oncol Biol Phys 1991;20:1219-27.
109. Schwarer AP, Hughes JM, Trotman-Dickenson B, Krausz T, Goldman JM. A chronic pulmonary syndrome associated with graft-versus-host disease after allogeneic marrow transplantation. Transplantation 1992;54:1002-8.
110. Curtis DJ, Smale A, Thien F, Schwarer AP, Szer J. Chronic airflow obstruction in long-term survivors of allogeneic bone marrow transplantation. Bone Marrow Transplant 1995;16:169-73.
111. Beinert T, Dull T, Wolf K, Holler E, Vogelmeier C, Behr J, Kolb H. Late pulmonary impairment following allogeneic bone marrow transplantation. Eur J Med Res 1996;1:343-8.
112. Duncker C, Dohr D, Harsdorf S, Duyster J, Stefanic M, Martini C, Treiber M, Hertenstein B, Novotny J, Arnold R, Heimpel H, Bergmann L, Bunjes D. Non-infectious lung complications are closely associated with chronic graft-versus-host disease: a single center study of incidence, risk factors and outcome. Bone Marrow Transplant 2000;25:1263-8.
113. Michel O, Kips J, Duchateau J, Vertongen F, Robert L, Collet H, Pauwels R, Sergysels R. Severity of asthma is related to endotoxin in house dust. Am J Respir Crit Care Med 1996;154:1641-6.
114. Kline JN, Cowden JD, Hunninghake GW, Schutte BC, Watt JL, Wohlford-Lenane CL, Powers LS, Jones MP, Schwartz DA. Variable airway responsiveness to inhaled lipopolysaccharide. Am J Respir Crit Care Med 1999;160:297-303.
115. Becker S, Clapp WA, Quay J, Frees KL, Koren HS, Schwartz DA. Compartmentalization of the inflammatory response to inhaled grain dust. Am J Respir Crit Care Med 1999;160:1309-18.
116. Gereda JE, Klinnert MD, Price MR, Leung DY, Liu AH. Metropolitan home living conditions associated with indoor endotoxin levels. J Allergy Clin Immunol 2001;107:790-6.
117. Heinrich J, Gehring U, Douwes J, Koch A, Fahlbusch B, Bischof W, Wichmann HE, INGA-Study G. Pets and vermin are associated with high endotoxin levels in house dust. Clin Exp Allergy 2001;31:1839-45.
118. Park JH, Gold DR, Spiegelman DL, Burge HA, Milton DK. House dust endotoxin and wheeze in the first year of life. Am J Respir Crit Care Med 2001;163:322-8.
119. Russell RE, Culpitt SV, DeMatos C, Donnelly L, Smith M, Wiggins J, Barnes PJ. Release and activity of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 by alveolar macrophages from patients with chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 2002;26:602-9.
120. Vernooy JH, Dentener MA, van Suylen RJ, Buurman WA, Wouters EF. Long-term intratracheal lipopolysaccharide exposure in mice results in chronic lung inflammation and persistent pathology. Am J Respir Cell Mol Biol 2002;26:152-9.
121. Chien JW, Zhao LP, Hansen JA, Fan WH, Parimon T, Clark JG. Genetic variation in bactericidal/permeability-increasing protein influences the risk of developing rapid airflow decline after hematopoietic cell transplantation. Blood 2006;107:2200-7.
122. Swarbrick MM, Vaisse C. Emerging trends in the search for genetic variants predisposing to human obesity (review). Curr Opin Clin Nutr Metab Care 2003;6:369-75.